News

A 3-year-old boy with progressive familial intrahepatic cholestasis type 3 (PFIC3) was safety and effectively treated with a liver transplant from his mother after failing…

Two Phase 3 clinical trials testing pegozafermin in people with metabolic dysfunction-associated steatohepatitis (MASH), a severe manifestation of fatty liver disease, are enrolling participants,…

A team of researchers has developed a new screening system to identify previously unrecognized mutations as the likely cause of Alagille syndrome. In a…

The U.S. Food and Drug Administration (FDA) has given Gigagen the go-ahead to start clinical testing of GIGA-2339, its experimental treatment for hepatitis B…

The experimental therapy CM-101 is generally safe and results in signs of improvement in liver health and health of the ducts that transport the…

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to IN016, an experimental therapy Innorna is developing for progressive familial…

Pemvidutide, Altimmune’s experimental therapy, significantly reduced liver fat and inflammation, as well as body weight, among overweight or obese people with metabolic dysfunction-associated…

Having persistently high blood levels of bilirubin, a marker of liver damage, a year after undergoing a corrective liver surgery called the Kasai procedure increases…

In its efforts to connect diagnosed but untreated hepatitis B or C patients with physicians, the Center for Disease Analysis (CDA) Foundation has…

A European Medicines Agency (EMA) committee has recommended the approval of Ipsen‘s Iqirvo (elafibranor) as a second-line therapy for adults with primary biliary…